The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Open accessAbstract
Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life. It is a unique malignancy in that infants often present with either localized or metastatic disease that can spontaneously regress without intervention while older children can succumb to the disease after months to years of arduous therapy. Given this wide range of outcomes, the International Neuroblastoma Risk Group was created to stratify patients based on presenting characteristics and tumor biology in order to guide intensity of treatment strategies. The goal has been to decrease therapy for low-risk patients to avoid long-term complications while augmenting and targeting therapies for high-risk patients to improve overall survival. The international risk stratification depends on age, stage, histology, MYCN gene amplification status, tumor cell ploidy and segmental chromosomal abnormalities. Treatment for asymptomatic low-risk patients with an estimated survival of > 98% is often observation or surgical resection alone, whereas intermediate-risk patients with an estimated survival of > 90% require moderate doses of response-adjusted chemotherapy along with resection. High-risk patients undergo multiple cycles of combination chemotherapy before surgery, followed by consolidation with myeloablative autologous hematopoietic stem cell transplantation and local radiation and finally immunotherapy with differentiation therapy as maintenance phase. With this approach, outcome for patients with neuroblastoma has improved, as the field continues to expand efforts in more targeted therapies for high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Self-citationMatthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationIdentification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Self-citationThe International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Self-citationOncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Self-citationSomatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J. L., Sand, F., Heuckmann, J. M., et al. (2015) · Nature · doi:10.1038/nature14980 · Cited by 595
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589
Self-citationChromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Self-citationHeczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Metastatic Sites in Stage IV and IVS Neuroblastoma Correlate With Age, Tumor Biology, and Survival
DuBois, S. G., Kalika, Y., Lukens, J. N., Brodeur, G. M., Seeger, R. C., Atkinson, J. B., Haase, G. M., Black, C. T., Perez, C., Shimada, H., et al. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199905000-00005 · Cited by 433
Self-citationAmbros, P. F., Ambros, I. M., Brodeur, G. M., Haber, M., Khan, J., Nakagawara, A., Schleiermacher, G., Speleman, F., Spitz, R., London, W. B., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605014 · Cited by 404
Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Park, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., Burchill, S., Boubaker, A., McHugh, K., Nuchtern, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0177 · Cited by 365
Self-citationGermline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Screening of Infants and Mortality Due to Neuroblastoma
Woods, W. G., Gao, R.-N., Shuster, J. J., Robison, L. L., Bernstein, M., Weitzman, S., Bunin, G., Levy, I., Brossard, J., Dougherty, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012387 · Cited by 356
Ladenstein, R., Pötschger, U., Pearson, A. D. J., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30070-0 · Cited by 350
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24433 · Cited by 332
Hero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311
Kreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationShimada, H., Umehara, S., Monobe, Y., Hachitanda, Y., Nakagawa, A., Goto, S., Gerbing, R. B., Stram, D. O., Lukens, J. N., & Matthay, K. K. (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s · Cited by 294
Self-citationDrugging MYCN through an Allosteric Transition in Aurora Kinase A
Gustafson, W. C., Meyerowitz, J. G., Nekritz, E. A., Chen, J., Benes, C., Charron, E., Simonds, E. F., Seeger, R., Matthay, K. K., Hertz, N. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.015 · Cited by 278
Self-citationMody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30355-8 · Cited by 277
Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
Self-citationCole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Strother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234
Self-citationMatthay, K. K., Shulkin, B., Ladenstein, R., Michon, J., Giammarile, F., Lewington, V, Pearson, A. D. J., & Cohn, S. L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605621 · Cited by 225
Self-citationYanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., Villablanca, J. G., Maris, J. M., Park, J. R., Cohn, S. L., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112334 · Cited by 211
Self-citationGeorge, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Nuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Schleiermacher, G., Mosseri, V, London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.375 · Cited by 192
Self-citationInfarinato, N. R., Park, J. H., Krytska, K., Ryles, H. T., Sano, R., Szigety, K. M., Li, Y., Zou, H. Y., Lee, N. V., Smeal, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1056 · Cited by 183
Pritchard, J., Cotterill, S. J., Germond, S. M., Imeson, J., de Kraker, J., & Jones, D. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20219 · Cited by 183
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1449 · Cited by 183
177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
Gains, J. E., Bomanji, J. B., Fersht, N. L., Sullivan, T., D'Souza, D., Sullivan, K. P., Aldridge, M., Waddington, W., & Gaze, M. N. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085100 · Cited by 170
von Allmen, D., Davidoff, A. M., London, W. B., Van Ryn, C., Haas-Kogan, D. A., Kreissman, S. G., Khanna, G., Rosen, N., Park, J. R., & La Quaglia, M. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2642 · Cited by 167
Ladenstein, R., Philip, T., Lasset, C., Hartmann, O., Garaventa, A., Pinkerton, R., Michon, J., Pritchard, J., Klingebiel, T., Kremens, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.953 · Cited by 165
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
Federico, S. M., McCarville, M. B., Shulkin, B. L., Sondel, P. M., Hank, J. A., Hutson, P., Meagher, M., Shafer, A., Ng, C. Y., Leung, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0379 · Cited by 162
A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
Wilson, J. S., Gains, J. E., Moroz, V., Wheatley, K., & Gaze, M. N. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.016 · Cited by 161
HANN, H.-W. L., Evans, A. E., Siegel, S. E., Wong, K. Y., Sather, H. N., Dalton, A., Hammond, D., & Seeger, R. C. (1985) · PubMed · Cited by 160
Bagatell, R., London, W. B., Wagner, L. M., Voss, S. D., Stewart, C. F., Maris, J. M., Kretschmar, C., & Cohn, S. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7107 · Cited by 160
Sholler, G. L. S., Gerner, E. W., Bergendahl, G., MacArthur, R. B., VanderWerff, A., Ashikaga, T., Bond, J. P., Ferguson, W. S., Roberts, W. D., Wada, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127246 · Cited by 152
Kushner, B. H., Cheung, I. Y., Modak, S. I., Kramer, K., Ragupathi, G., & Cheung, N. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1012 · Cited by 147
Simon, T., Häberle, B., Hero, B., von Schweinitz, D., & Berthold, F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9339 · Cited by 143
Park, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142
Self-citationGaze, M. N., Chang, Y.-C., Flux, G., Mairs, R. J., Saran, F. H., & Meller, S. T. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.195 · Cited by 141
Bernardi, B. D., Gerrard, M., Boni, L., Rubie, H., Cañete, A., Cataldo, A. D., Castel, V., Lacerda, A., Ladenstein, R. L., Ruud, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5877 · Cited by 141
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
Kushner, B. H., Kramer, K., Modak, S. I., & Cheung, N. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7272 · Cited by 137
London, W. B., Frantz, C. N., Campbell, L., Seeger, R. C., Brumback, B., Cohn, S. L., Matthay, K. K., Castleberry, R. P., & Diller, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5016 · Cited by 136
Self-citationBagatell, R., Popovic, M. B., London, W. B., Zhang, Y., Pearson, A. D. J., Matthay, K. K., Monclair, T. F., Ambros, P. F., & Cohn, S. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9184 · Cited by 136
Self-citationSerum ferritin as a guide to therapy in neuroblastoma.
HANN, H.-W. L., Levy, H. M., & Evans, A. E. (1980) · PubMed · Cited by 135
DuBois, S. G., Marachelian, A., Fox, E., Kudgus, R. A., Reid, J. M., Groshen, S. G., Malvar, J., Bagatell, R., Wagner, L. M., Maris, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.4889 · Cited by 132
Self-citationCombination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
Russell, M. R., Levin, K., Rader, J., Belcastro, L. T., Li, Y., Martínez, D., Pawel, B., Shumway, S. D., Maris, J. M., & Cole, K. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2669 · Cited by 130
Efficacy of complete resection for high-risk neuroblastoma: a children’s cancer group study
Adkins, E. S., Sawin, R. S., Gerbing, R. B., London, W. B., Matthay, K. K., & Haase, G. M. (2004) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2004.02.041 · Cited by 123
Self-citationMossé, Y. P., Lipsitz, E. G., Fox, E., Teachey, D. T., Maris, J. M., Weigel, B. J., Adamson, P. C., Ingle, M. A., Ahern, C. H., & Blaney, S. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3251 · Cited by 120
Minturn, J. E., Evans, A. E., Villablanca, J. G., Yanik, G. A., Park, J. R., Shusterman, S., Groshen, S. G., Hellriegel, E. T., Bensen-Kennedy, D. M., Matthay, K. K., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1581-4 · Cited by 105
Self-citationTargeting Ornithine Decarboxylase Impairs Development of MYCN -Amplified Neuroblastoma
Rounbehler, R. J., Li, W., Hall, M. A., Yang, C., Fallahi, M., & Cleveland, J. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2968 · Cited by 103
Decarolis, B., Schneider, C., Hero, B., Simon, T., Volland, R., Roels, F., Dietlein, M., Berthold, F., & Schmidt, M. C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8794 · Cited by 102
Synaptophysin and neurofilament proteins as markers for neuroendocrine tumors.
Miettinen, M. (1987) · PubMed · Cited by 100
Morgenstern, D. A., London, W. B., Stephens, D., Volchenboum, S. L., Simon, T., Nakagawara, A., Shimada, H., Schleiermacher, G., Matthay, K. K., Cohn, S. L., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.005 · Cited by 95
Self-citationPolyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression
Evageliou, N. F., Haber, M., Vu, A. T., Laetsch, T. W., Murray, J. E., Gamble, L. D., Cheng, N. C., Liu, K., Reese, M., Corrigan, K. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2539 · Cited by 93
Maurer, B. J., Kang, M. H., Villablanca, J. G., Janeba, J., Groshen, S. G., Matthay, K. K., Sondel, P. M., Maris, J. M., Jackson, H. A., Goodarzian, F., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24643 · Cited by 89
Self-citationParacrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Chanthery, Y. H., Gustafson, W. C., Itsara, M., Persson, A. I., Hackett, C. S., Grimmer, M., Charron, E., Yakovenko, S., Kim, G., Matthay, K. K., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002977 · Cited by 84
Self-citationYanik, G. A., Parisi, M. T., Naranjo, A. H., Nadel, H. R., Gelfand, M. J., Park, J. R., Ladenstein, R. L., Pöetschger, U., Boubaker, A., Valteau‐Couanet, D., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195883 · Cited by 84
Self-citationDuBois, S. G., Groshen, S. G., Park, J. R., Haas-Kogan, D. A., Yang, X., Geier, E. G., Chen, E., Giacomini, K., Weiss, B., Cohn, S. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3240 · Cited by 75
Self-citationPatterson, D. M., Gao, D., Trahan, D. N., Johnson, B. A., Ludwig, A. D., Barbieri, E., Chen, Z., Diaz-Miron, J. L., Vassilev, L. T., Shohet, J. M., et al. (2011) · Angiogenesis · doi:10.1007/s10456-011-9210-8 · Cited by 70
Zhou, M. J., Doral, M. Y., DuBois, S. G., Villablanca, J. G., Yanik, G. A., & Matthay, K. K. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.023 · Cited by 68
Self-citationAmoroso, L., Erminio, G., Makin, G., Pearson, A. D. J., Brock, P. R., Valteau‐Couanet, D., Castel, V., Pasquet, M., Laureys, G., Thomas, C., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.511 · Cited by 67
Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A. H., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D. A., Shaw, P. J., Geiger, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba3 · Cited by 66
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Wagner, L. M., & Adams, V. R. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s124008 · Cited by 63
Giannatale, A. D., Dias, N., Devos, A. S., Hugh, K. M., Boubaker, A., Courbon, F., Verschuur, A., Ducassoul, S., Malekzadeh, K., Casanova, M., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.012 · Cited by 62
Siebert, N., Eger, C., Seidel, D., Jüttner, M., Zumpe, M., Wegner, D., Kietz, S., Ehlert, K., Veal, G. J., Siegmund, W., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1130196 · Cited by 59
Modak, S. I., Kushner, B. H., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26448 · Cited by 58
Talleur, A. C., Triplett, B. M., Federico, S. M., Mamcarz, E. K., Janssen, W. E., Wu, J., Shook, D. R., Leung, W. H., & Furman, W. L. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.011 · Cited by 53
Seif, A. E., Naranjo, A. H., Baker, D. L., Bunin, N., Kletzel, M., Kretschmar, C., Maris, J. M., McGrady, P., von Allmen, D., Cohn, S. L., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.276 · Cited by 50
Mullassery, D., Farrelly, P. J., & Losty, P. D. (2014) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2014.947009 · Cited by 47
Meany, H. J., London, W. B., Ambros, P. F., Matthay, K. K., Monclair, T. F., Simon, T., Garaventa, A., Berthold, F., Nakagawara, A., Cohn, S. L., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25134 · Cited by 42
Self-citationFranscini, L. C., Vazquez-Montes, M., Buclin, T., Perera, R., Dunand, M., Grouzmann, E., & Popovic, M. B. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25385 · Cited by 41
Is there a role for PET-CT and SPECT-CT in pediatric oncology?
Biermann, M., Schwarzlmüller, T., Fasmer, K. E., Reitan, B. C., Johnsen, B., & Rosendahl, K. (2013) · Acta Radiologica · doi:10.1258/ar.2012.120616 · Cited by 41
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Sander, J., Treuner, J., & Michaelis, J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00077-6 · Cited by 35
Liu, Y.-L., Lu, M., Chang, H., Lu, C., Lin, D., Jou, S., Yang, Y., Lee, Y., Huang, S.-F. K., Jeng, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7933 · Cited by 33
Kakodkar, N. C., Peddinti, R., Tian, Y., Guerrero, L. J., Chlenski, A., Yang, Q., Salwen, H. R., Maitland, M. L., & Cohn, S. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24004 · Cited by 30
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
Cervantes-Madrid, D., Szydzik, J., Lind, D. E., Borenäs, M., Bemark, M., Cui, J., Palmer, R. H., & Hallberg, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-55060-7 · Cited by 30
Erdreich‐Epstein, A., Singh, A. R., Joshi, S., Vega, F. M. D. L., Guo, P., Xu, J., Groshen, S. G., Ye, W., Millard, M., Campan, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13386 · Cited by 28
Saarinen‐Pihkala, U. M., Hovi, L., Koivusalo, A., Jahnukainen, K., Karikoski, R., Sariola, H. V., & Wikström, S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24173 · Cited by 21
Li, J., Ye, J., Zhu, S., & Cui, H. (2019) · Cells · doi:10.3390/cells8090955 · Cited by 18
Cited by
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Suh, J. K., Koh, K., Min, S. Y., Kim, Y. S., Kim, H., Im, H. J., Namgoong, J., Kim, D. Y., Ahn, S. D., Lee, J. J., et al. (2020) · Pediatric Transplantation · doi:10.1111/petr.13658 · Cited by 22
Metadata
- Authors
- Tolbert, V. P., & Matthay, K. K.
- Venue
- Cell and Tissue Research
- Published
- 2018-03-23
- Volume
- 372
- Issue
- 2
- Pages
- 195-209
- ISSN
- 0302-766X (ISSN-L)
- 1432-0878
- OpenAlex
- W2793376960
- Cited by
- 304
- References
- 107
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.